STAT January 19, 2026
Elizabeth Cooney

Durable solution to metabolic conditions may be underused, authors suggest, while drugs evolve

When endocrinologist Mary Elizabeth Patti looks at a patient with type 2 diabetes who could benefit from weight loss, she sees more than body mass index and blood glucose levels. She also recognizes the challenges of social vulnerability, understanding how low income, food insecurity, and limited access to health care might matter in treatment choice. After all, those factors are strongly linked to developing type 2 diabetes and obesity in the first place.

For more than a dozen years, Patti has been a leader of long-running randomized clinical trials conducted in four U.S. cities that compared bariatric surgery to medication and lifestyle management for type 2 diabetes....

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

 
Topics: Biotechnology, Patient / Consumer, Pharma / Biotech, Provider, Survey / Study, Trends
The 250 best hospitals, according to Healthgrades
How HTM will power resilient health systems in 2026
Around the nation: Amazon's One Medical launches new AI chatbot
Physician assistants say paperwork and AI training still lag
Telehealth Claims Are Declining, What’s Next For Virtual Mental Health Care?

Share Article